$1.600
+0.235 (+14.70%)收盘时
NRSN 同业对比
In the context of the broader market, NRSN competes directly with industry leaders such as ERNA and KALA. With a market capitalization of $3.04M, it holds a significant position in the sector. When comparing efficiency, NRSN's gross margin of N/A stands against ERNA's N/A and KALA's N/A. Such benchmarking helps identify whether Neurosense Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
Neurosense Therapeutics Ltd 财务表现
Neurosense has reported consistent net losses, with a net income of -3.56 million in the first half of 2026, indicating ongoing financial struggles. The current ratio has dropped to 0.28, highlighting liquidity issues.
Financials
FY2024Q4
0.00
Total Revenue
FY2025Q4
YoY:
+80.49%
-3.20M
Operating Profit
FY2025Q4
YoY:
+78.12%
-3.21M
Net Income after Tax
FY2024Q3
YoY:
+339.22%
-2.24
EPS - Diluted
FY2025Q4
-1.84M
Free Cash Flow
FY2025Q3
463.98
ROIC
相关文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。